Article

Passive Immunoprotection of Plasmodium falciparum-Infected Mice Designates the CyRPA as Candidate Malaria Vaccine Antigen

Swiss Tropical and Public Health Institute, CH-4051 Basel, Switzerland.
The Journal of Immunology (Impact Factor: 4.92). 05/2012; 188(12):6225-37. DOI: 10.4049/jimmunol.1103177
Source: PubMed

ABSTRACT

An effective malaria vaccine could prove to be the most cost-effective and efficacious means of preventing severe disease and death from malaria. In an endeavor to identify novel vaccine targets, we tested predicted Plasmodium falciparum open reading frames for proteins that elicit parasite-inhibitory Abs. This has led to the identification of the cysteine-rich protective Ag (CyRPA). CyRPA is a cysteine-rich protein harboring a predicted signal sequence. The stage-specific expression of CyRPA in late schizonts resembles that of proteins known to be involved in merozoite invasion. Immunofluorescence staining localized CyRPA at the apex of merozoites. The entire protein is conserved as shown by sequencing of the CyRPA encoding gene from a diverse range of P. falciparum isolates. CyRPA-specific mAbs substantially inhibited parasite growth in vitro as well as in a P. falciparum animal model based on NOD-scid IL2Rγ(null) mice engrafted with human erythrocytes. In contrast to other P. falciparum mouse models, this system generated very consistent results and evinced a dose-response relationship and therefore represents an unprecedented in vivo model for quantitative comparison of the functional potencies of malaria-specific Abs. Our data suggest a role for CyRPA in erythrocyte invasion by the merozoite. Inhibition of merozoite invasion by CyRPA-specific mAbs in vitro and in vivo renders this protein a promising malaria asexual blood-stage vaccine candidate Ag.

Full-text preview

Available from: jimmunol.org
  • Source
    • "VLP platforms are also reviewed elsewhere in this series[Wu et al.]. Furthermore , the recent elucidation of a protein complex containing PfRH5 and two binding partners – PfRH5-interacting protein (PfRipr) and the GPI-anchored cysteine-rich protective antigen/PfRH5-PfRipr membrane-anchoring protein (PfCyRPA/PfRRMAP)[98,99], suggests further opportunities to improve vaccine potency – both antigens elicit functional antibodies alone[82,9899100, and IgG responses induced in rats by PfRH5 and PfCyRPA proteins produced in E. coli have been shown to synergize[75,99]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Plasmodium parasites are the causative agent of human malaria, and the development of a highly effective vaccine against infection, disease and transmission remains a key priority. It is widely established that multiple stages of the parasite's complex lifecycle within the human host and mosquito vector are susceptible to vaccine-induced antibodies. The mainstay approach to antibody induction by subunit vaccination has been the delivery of protein antigen formulated in adjuvant. Extensive efforts have been made in this endeavor with respect to malaria vaccine development, especially with regard to target antigen discovery, protein expression platforms, adjuvant testing, and development of soluble and virus-like particle (VLP) delivery platforms. The breadth of approaches to protein-based vaccines is continuing to expand as innovative new concepts in next-generation subunit design are explored, with the prospects for the development of a highly effective multi-component/multi-stage/multi-antigen formulation seeming ever more likely. This review will focus on recent progress in protein vaccine design, development and/or clinical testing for a number of leading malaria antigens from the sporozoite-, merozoite- and sexual-stages of the parasite's lifecycle-including PfCelTOS, PfMSP1, PfAMA1, PfRH5, PfSERA5, PfGLURP, PfMSP3, Pfs48/45 and Pfs25. Future prospects and challenges for the development, production, human delivery and assessment of protein-based malaria vaccines are discussed.
    Full-text · Article · Oct 2015 · Vaccine
  • [Show abstract] [Hide abstract]
    ABSTRACT: An ideal malaria vaccine would prevent disease and reduce transmission by targeting several developmental stages of human malaria parasites. To be cost-effective, a modular antigen delivery technology is required for the development of such a multivalent subunit vaccine. In this review, we summarize and discuss a strategy to develop synthetic peptidomimetics of key malaria target antigens for inclusion in a multivalent malaria subunit vaccine based on immunopotentiating reconstituted influenza virosomes. Clinical testing of a bivalent virosomal formulation incorporating two structurally optimized peptidomimetics has demonstrated safety, immunogenicity and pilot efficacy. While this clinical validation supports the concept of using peptide-loaded virosomes for vaccination in humans, it is assumed that additional antigens will have to be added to the bivalent formulation to generate a highly effective malaria vaccine.
    No preview · Article · Aug 2012 · Future Virology
  • Source

    Full-text · Article · Oct 2012 · Malaria Journal
Show more